Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 412

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Open access
Huang, Wei-Sheng, Liu, Shuangying, Zou, Dong, Thomas, Mathew, Wang, Yihan, Zhou, Tianjun, Romero, Jan, Kohlmann, Anna, Li, Feng, Qi, Jiwei, Cai, Lisi, Dwight, Timothy A., Xu, Yongjin, Xu, Rongsong, Dodd, Rory, Toms, Angela, Parillon, Lois, Lu, Xiaohui, Anjum, Rana, Zhang, Sen, Wang, Frank, Keats, Jeffrey, Wardwell, Scott D., Ning, Yaoyu, Xu, Qihong, Moran, Lauren E., Mohemmad, Qurish K., Jang, Hyun Gyung, Clackson, Tim, Narasimhan, Narayana I., Rivera, Victor M., Zhu, Xiaotian, Dalgarno, David, Shakespeare, William C.·2016·Journal of Medicinal Chemistry

Abstract

In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.6b00306

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 412

Metadata

Authors
Huang, W.-S., Liu, S., Zou, D., Thomas, M., Wang, Y., Zhou, T., Romero, J., Kohlmann, A., Li, F., Qi, J., Cai, L., Dwight, T. A., Xu, Y., Xu, R., Dodd, R., Toms, A., Parillon, L., Lu, X., Anjum, R., Zhang, S., Wang, F., Keats, J., Wardwell, S. D., Ning, Y., Xu, Q., Moran, L. E., Mohemmad, Q. K., Jang, H. G., Clackson, T., Narasimhan, N. I., Rivera, V. M., Zhu, X., Dalgarno, D., & Shakespeare, W. C.
Venue
Journal of Medicinal Chemistry
Published
2016-05-12
Volume
59
Issue
10
Pages
4948-4964
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2345320779
Cited by
412
References
4
FWCI
27.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. https://app.cochat.ai/papers/10.1021/acs.jmedchem.6b00306
The paper
Huang, W.-S., Liu, S., Zou, D., Thomas, M., Wang, Y., Zhou, T., Romero, J., Kohlmann, A., Li, F., Qi, J., Cai, L., Dwight, T. A., Xu, Y., Xu, R., Dodd, R., Toms, A., Parillon, L., Lu, X., Anjum, R., . . . Shakespeare, W. C. (2016). Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6b00306

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.